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fractional shortening (FS) two standard deviations below the
age adjusted mean (3) >10% decrease in EF or FS at day 100
from baseline.
Results: 92 of 100 consecutive patients completed day 100
screening (8 died). 25% (23 of 92) had LV dysfunction at day
100 (Table). 96%(22 of 23) were asymptomatic at time of
screening. Patients with LV dysfunction were older at the
time of SCT than those without (p¼0.068). Patients receiving
PBSC grafts had an increased incidence of LV dysfunction (p¼
0.032), likely related to the diagnosis of those patients (ma-
lignancy receiving autologous SCT and Fanconi Anemia).
Overall, however, diagnosis was not signiﬁcantly associated
with LV dysfunction. Patients with previous anthracycline
exposure had increased LV dysfunction compared to those
without (48% vs. 26%). GVHD, engraftment syndrome, and
viremias in the ﬁrst 100 days were not signiﬁcantly associ-
ated with decreased RV function. Death at 1 year was similar
in both groups.
Discussion: 25% of patients showed signs of cardiac
dysfunction at day 100, which was higher than anticipated.
Although there were no acute differences in outcome, the
long-term complications are unknown. Echocardiography at
day 100 identiﬁes SCT cardiac dysfunction, however, more
research is needed to understand the overall impact on long-
term outcome.288
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Background: Sleep disruption can adversely affect meta-
bolism, psychological well-being, performance, inﬂamma-
tory cytokines, immune function, and cardiac function and is
likely overlooked as a side effect of stem cell transplantation
(SCT). There are no objective studies evaluating sleep in pe-
diatric SCT patients. Actigraphic monitoring utilizes a small
monitor that is worn like a wristwatch and when used in
combination with self-reports of bedtime and rising time,
has been found to be a reliable and valid measure of sleep
patterns.
Purpose: To evaluate sleep patterns in SCT children and
young adults through actigraphy, sleep diaries, and evalua-
tion of environmental factors that inﬂuence sleep disruption.
Methods: Objective sleep parameters were measured with
the Micro-Motionlogger SleepWatch (Ambulatory Moni-
toring, Inc.) actigraph which was worn continuously. Sleep-
wake patterns were reported in a sleep diary to allow for
screening of artifacts (e.g., actigraph removal). The number ofwaking episodes per cycle of sleep, duration of sleep, mi-
nutes of sleep, and sleep efﬁciency (Abnormal is< 90%) were
calculated using actigraphy data. Room entry checklists were
utilized to record the frequency of nocturnal room entries in
a separate cohort of patients on randomly-selected nights on
the BMT unit.
Results:We obtained 71 nights of sleep for eight patients. Six
patients (75%) were male with a median age of 12.4 years
(IQR 10.6-14.1) at time of actigraphy. Thirty-six nights (51%)
were pretransplant, 35 nights (49%) were post-transplant.
The average sleep onset time was midnight with an average
rise time of 9:00 am. The median duration from onset to
offset was 9.1 hours (IQR 8.0-10.2) with a median duration of
7.1 hours (IQR 6.1-7.8). The median number of waking epi-
sodes per sleep cycle was 12 (IQR 9-17). Median sleep efﬁ-
cacy was 80.7% (IQR 70 to 89%); sleep efﬁciency was
abnormally low 75% of the nights. During 189 nights of room
monitoring, patient’s rooms were entered a median of 12
times per night (IQR 10-15).
Conclusions: These preliminary data suggest that pediatric
patients undergoing SCT often have poor sleep quality while
hospitalized. Frequent room entries, amongst other causes,
may contribute to sleep disruption. Further research is
needed to fully understand the impact of sleep disruption
after HSCT, and evaluate potential interventions to improve
sleep quality.289
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Background: In 2013, the Centers for Disease Control and
Prevention developed a modiﬁcation of blood stream infec-
tion (BSI) deﬁnition, termed mucosal barrier injury labora-
tory-conﬁrmed bloodstream infection (MBI-LCBI). In January
of 2013, the National Healthcare Safety Network (NHSN)
integrated a MBI-LCBI deﬁnition into the methods for BSI
surveillance to aid in identiﬁcation of BSIs reported as central
line associated blood stream infections (CLABSI) likely
related to mucosal barrier injury. There is little literature
describing the timing, patients at risk, and incidence of MBI-
LCBIs in comparison to CLABSIs and BSIs from a secondary
source (secondary BSIs).
